Allergy/Immunology · Tucson, AZ
NPI
1467485169
Since 2006
Specialty
Allergy/Immunology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2960 N Country Club Rd
Tucson, AZ, 85716
Phone (520) 325-5701
Groups this clinician bills Medicare through
Medicare paid, 2024
$390K
27,618 services
Medicare patients, 2024
391
Average age 74
Drug cost, 2024
$3.9M
1,866 prescriptions
Company payments, 2025
$157K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amy Wagelie Steffen was code 95165 (treatment - miscellaneous), 6,443 times for 231 patients. In total Amy Wagelie Steffen billed 27,618 services in 29 codes, and Medicare paid $390K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95165 Treatment - Miscellaneous | Office | 6,443 | 231 | $9.76 | $63K |
| 95004 Test - Miscellaneous | Office | 2,762 | 51 | $2.64 | $7,279 |
| 95117 Treatment - Miscellaneous | Office | 2,201 | 120 | $7.80 | $17K |
| 95024 Test - Miscellaneous | Office | 682 | 35 | $5.56 | $3,789 |
| 95115 Treatment - Miscellaneous | Office | 232 | 14 | $6.99 | $1,621 |
| 99213 Office E&M - Established | Office | 202 | 188 | $63.33 | $13K |
| 99214 Office E&M - Established | Office | 197 | 160 | $86.40 | $17K |
| 96372 Injection Administration | Office | 176 | 21 | $9.56 | $1,682 |
| 95012 Pulmonary | Office | 121 | 91 | $12.96 | $1,568 |
| 94010 Pulmonary Function Testing | Office | 109 | 83 | $18.65 | $2,033 |
| 96401 Chemotherapy Administration | Office | 97 | 14 | $49.78 | $4,829 |
| 99204 Office E&M - New | Office | 22 | 22 | $106.30 | $2,339 |
By year: 2022 $392K for 26,701 services; 2023 $442K for 31,007 services; 2024 $390K for 27,618 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amy Wagelie Steffen prescribed most often to Medicare patients was Montelukast Sodium, with 236 prescriptions and refills. In total Amy Wagelie Steffen wrote 1,866 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 236 | 607 | 62 | $3,304 |
| Xolair Omalizumab | 156 | 157 | 16 | $460K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 123 | 157 | 61 | $4,875 |
| Fluticasone Propionate Generic | 101 | 202 | 41 | $2,092 |
| Azelastine Hcl Generic | 90 | 151 | 33 | $2,579 |
| Tezspire Tezepelumab-Ekko | 86 | 86 | Under 11 | $359K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 85 | 107 | 23 | $69K |
| Breo Ellipta Fluticasone/Vilanterol | 78 | 121 | 21 | $46K |
| Ipratropium Bromide Generic | 70 | 107 | 22 | $2,336 |
| Symbicort Budesonide/Formoterol Fumarate | 67 | 94 | 20 | $20K |
| Spiriva Respimat Tiotropium Bromide | 57 | 100 | 14 | $51K |
| Famotidine Generic | 45 | 84 | 18 | $372 |
| Prednisone Generic | 41 | 47 | 18 | $228 |
| Dupixent Syringe Dupilumab | 40 | 40 | Under 11 | $153K |
| Hydroxyzine Hcl Generic | 40 | 44 | Under 11 | $645 |
Brand drugs: 924 claims; generic drugs: 942 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amy Wagelie Steffen $157K ($157K in general payments such as food, travel and fees) from 18 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $127K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 121 | $127K |
| Genzyme Corporation SNY | 12 | $11K |
| Regeneron Healthcare Solutions, Inc. REGN | 18 | $8,596 |
| Genentech USA, Inc. ROG.SW | 15 | $8,541 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $1,119 |
| Amgen Inc. AMGN | 9 | $160 |
| CSL Behring CSL.AX | 2 | $50.79 |
| ADMA BioManufacturing LLC | 4 | $42.45 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 2 | $35.54 |
| Viatris Specialty LLC | 1 | $25.39 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.